Symptomatic anemia occurred in a patient with a renal transplant 6 weeks after commencing therapy with Losartan Potassium. Decreased hemoglobin concentrations have also been reported in patients with severe renal impairment undergoing hemodialysis.
Raised liver enzyme values have occurred rarely in patients receiving Losartan Potassium. Severe, acute reversible hepatotoxicity occurred in a patient who had been taking Losartan in a dose of 150 mg daily for 6 weeks.
Atypical cutaneous lymphoid infiltrates, taste disturbances in some cases progressing to complete taste loss, it will return to normal after discontinuing therapy; migraine and acute pancreatitis have also been reported in patients receiving Losartan Potassium.
View ADR Reporting Link